In particular, the combination of METTL3 inhibitors or DLG2 activators with current cervical cancer therapies has the potential to improve treatment outcomes by leveraging a more comprehensive and targeted approach against the disease. The gene discussed is METTL3; the disease is cervical carcinoma.